Decoy Therapeutics Q2 net loss widens 148% to $2.37 million; revenue turns to $227,629 from no revenue
DCOY•Second-quarter results
Decoy Therapeutics posted a GAAP net loss of $2.37 million for the quarter ended June 30, 2026, widening 148% year over year.
Revenue rose to $227,629 from no revenue a year earlier, driven solely by a Gates Foundation grant.
Costs rise after merger
Research and development expense jumped to $1.3 million, up 1,021% year over year, on the post-merger addition of the IMP3ACT program.
General and administrative costs increased to $1.33 million, up 56% year over year, reflecting inclusion of Legacy Decoy operations.
Cash position and financing
Cash, cash equivalents and restricted cash totaled $8.3 million at June 30.
The company also raised $3.5 million gross in a June private placement.
